Why the Pharmaceutical Industry Needs AI
Few industries operate under the same combination of scientific complexity, regulatory oversight, and quality requirements as the pharmaceutical industry. Every stage of research, development, and manufacturing generates information that must be interpreted accurately before important decisions can be made. Since the amount of the collected information is growing, pharmaceutical companies turned to artificial intelligence to improve the speed, consistency, and scalability of these processes.
The increasing use of AI has also attracted the attention of regulators. In April 2026, the FDA issued a warning letter concerning the improper use of AI in quality and compliance processes. Although the case involved a cosmetics manufacturer, it demonstrated that regulators are beginning to examine not only the decisions made by AI systems, but also how those systems are developed, validated, monitored, and maintained. AI is now entering regulated environments where reliability, transparency, and traceability are expected throughout the system lifecycle.
While regulatory oversight is evolving, most organisations are adopting AI for operational reasons. Growing volumes of scientific data, increasingly complex manufacturing processes, and pressure to improve efficiency have made manual analysis increasingly difficult to scale.
AI Supports Better Operational Decisions
Every stage of pharmaceutical research and manufacturing generates data that influences important business decisions. Laboratory experiments produce microscopy images and analytical data. Manufacturing lines generate inspection images and process measurements. Quality teams review deviations, documentation, and production records before products can move forward.
Much of this information has traditionally relied on expert interpretation. Scientists evaluate experimental results, operators inspect products, and quality specialists review documentation before making decisions that directly affect product quality and patient safety.
AI enables organisations to analyse visual and operational data more consistently across large datasets, reducing the manual effort required for repetitive analysis while supporting experts in higher-value decision-making.
Computer Vision Has Become One Of The Most Important AI Technologies
Much of the information generated throughout pharmaceutical research and manufacturing is visual. As a result, computer vision has become one of the most widely adopted AI technologies across the industry.
Computer vision allows organisations to automate many of these activities while improving consistency and throughput. Rather than relying exclusively on manually defined inspection rules, modern systems learn to recognise visual patterns from representative data and apply that knowledge to new images.
Although both manufacturing inspection and scientific image analysis rely on computer vision, they present different technical challenges. Manufacturing inspection and microscopy, for example, require different datasets, validation strategies, and often different AI models.
Adopting AI Requires More Than Choosing A Model
There is rarely a single technical solution to an AI problem. The appropriate approach depends on the available data, operational requirements, existing infrastructure, and regulatory expectations.
Technical, operational, and regulatory constraints vary across pharmaceutical organisations. Available data, infrastructure, deployment requirements, performance expectations, and integration with existing workflows all influence which solution is appropriate.
In practice, the quality and representativeness of available data often have a greater influence on project outcomes than the choice of AI model. Consistent imaging conditions, well-defined datasets, and representative examples of real operating scenarios provide the foundation for reliable AI systems.
For this reason, AI projects benefit from evaluating existing technologies before introducing additional complexity. In many situations, proven models and established architectures already address a significant part of the problem. Where operational requirements cannot be met with existing solutions, additional optimization or custom development can then be introduced where it creates measurable value.
This principle is central to how we approach AI delivery at Visage Technologies. We begin by understanding the operational problem, evaluating available technologies, and validating feasibility before deciding where custom development is required. The objective is not to build AI for its own sake, but to identify the most effective path to a reliable production solution that delivers measurable business value.
AI As a Part of Pharmaceutical Infrastructure
AI became another operational capability within pharmaceutical organisations, alongside laboratory systems, manufacturing equipment, quality management systems, and enterprise software.
The long-term value of AI depends not only on model performance but also on how well it fits into everyday operations. Systems must integrate with existing workflows, support regulatory expectations, protect valuable research data, and remain maintainable as products, processes, and business requirements evolve.
Organizations that approach AI as part of their broader operational strategy are better positioned to realize lasting value from the technology. The discussion is no longer centered on whether AI has a role in pharmaceuticals. The focus is shifting towards identifying where it creates the greatest value and how it can be implemented responsibly within regulated environments.
